Press release
Chronic Myelomonocytic Leukaemia Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myelomonocytic Leukaemia Treatment Landscape. Click here to read more @ Chronic Myelomonocytic Leukaemia Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report
* In July 2025, Novartis Pharmaceuticals announced a study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
* DelveInsight's Chronic Myelomonocytic Leukaemia pipeline report depicts a robust space with 20+ Chronic Myelomonocytic Leukaemia companies working to develop 25+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.
* The leading Chronic Myelomonocytic Leukaemia Companies such as Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
* Promising Chronic Myelomonocytic Leukaemia Pipeline Therapies such as lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib, and others.
Stay informed about the cutting-edge advancements in Chronic Myelomonocytic Leukaemia Treatments. Download for updates and be a part of the revolution in oncology care @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Myelomonocytic Leukaemia Emerging Drugs Profile
* Timdarpacept: ImmuneOnco Biopharma
Timdarpacept is a recombinant Signal Regulatory Protein (SIRP) IgG1 fusion protein currently being evaluated as a treatment for CMML. This innovative therapeutic agent functions by blocking the ""Don't eat me"" signal and activating the ""Eat me"" signal, which enhances Antibody-Dependent Cellular Phagocytosis (ADCP) and promotes the immune system's ability to target and eliminate tumor cells. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Myelomonocytic Leukemia.
* IO-202: Immune-Onc Therapeutics
IO-202 is a first-in-class, humanized IgG1 monoclonal antibody designed to target the Leukocyte Immunoglobulin-Like Receptor Subfamily B4 (LILRB4), which is overexpressed in chronic myelomonocytic leukemia (CMML) cells. By binding with high affinity to LILRB4, IO-202 facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), enhancing the immune system's ability to eliminate malignant cells. The drug has received both fast track and orphan drug designations from the FDA, underscoring its potential as a therapeutic option for patients with CMML. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Chronic Myelomonocytic Leukemia.
* STX-0712: SOLU THERAPEUTICS, INC.
STX-0712 is an innovative therapeutic agent developed by Solu Therapeutics for the treatment of Chronic Myelomonocytic Leukemia (CMML). This drug is a CCR2-targeting Cytotoxicity Targeting Chimera (CyTAC) designed to selectively bind to CCR2, a receptor that is highly expressed on malignant monocytes in these hematologic cancers. The drug has shown robust activity in CMML, with favorable pharmacokinetics and tolerability observed in non-human primate models. Currently, the drug is in Preclinical stage of its development for the treatment of Chronic Myelomonocytic Leukemia.
The Chronic Myelomonocytic Leukaemia pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myelomonocytic Leukaemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myelomonocytic Leukaemia Treatment.
* Chronic Myelomonocytic Leukaemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Myelomonocytic Leukaemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myelomonocytic Leukaemia market.
Get a detailed analysis of the latest innovations in the Chronic Myelomonocytic Leukaemia pipeline. Explore DelveInsight's expert-driven report today! @ Chronic Myelomonocytic Leukaemia Unmet Needs [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Myelomonocytic Leukaemia Companies
Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc., and others.
Chronic Myelomonocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Chronic Myelomonocytic Leukaemia Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report
* Coverage- Global
* Chronic Myelomonocytic Leukaemia Companies- Novartis Pharmaceuticals, Treadwell Therapeutics, Nerviano Medical Sciences, NextCure, Inc., Kahr Medical, Faron Pharmaceuticals Ltd, HUTCHMED, Salarius Pharmaceuticals Inc., Newave Pharmaceutical Inc., Immune-Onc Therapeutics Inc ., and others.
* Chronic Myelomonocytic Leukaemia Pipeline Therapies- lenzilumab, AMG 176, Azacitidine, Pevonedistat, Decitabine, 5-Azacitidine, Tipifarnib , and others.
* Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Myelomonocytic Leukaemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Chronic Myelomonocytic Leukaemia Pipeline on our website @ Chronic Myelomonocytic Leukaemia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Chronic Myelomonocytic Leukemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Myelomonocytic Leukemia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Timdarpacept: ImmuneOnco Biopharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* IO-202: Immune-Onc Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* STX-0712: SOLU THERAPEUTICS, INC.
* Drug profiles in the detailed report.....
* Inactive Products
* Chronic Myelomonocytic Leukemia Key Companies
* Chronic Myelomonocytic Leukemia Key Products
* Chronic Myelomonocytic Leukemia- Unmet Needs
* Chronic Myelomonocytic Leukemia- Market Drivers and Barriers
* Chronic Myelomonocytic Leukemia- Future Perspectives and Conclusion
* Chronic Myelomonocytic Leukemia Analyst Views
* Chronic Myelomonocytic Leukemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-myelomonocytic-leukaemia-pipeline-outlook-report-2025-key-20-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myelomonocytic Leukaemia Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4125221 • Views: …
More Releases from ABNewswire
MISTORIKO VENTURES LLC: Real Estate Trends in Vienna
MISTORIKO VENTURES LLC explores current residential property trends in Vienna and future forecasts for real estate investors.
MISTORIKO VENTURES LLC presents a comprehensive examination of investment opportunities within Vienna's residential real estate sector for the forthcoming year of 2025. Vienna, distinguished by its profound cultural legacy and exemplary standards of living, maintains its position as a premier destination for both domestic and international capital seeking secure and profitable ventures.
The Viennese real…
Long Island Weight Loss Doctor Wins Four Major Awards for Natural Approach
NASSAU COUNTY, N.Y. - A Long Island weight loss Doctor , has earned four major industry awards in 2025, including Best of Long Island and the Excellence in Healthcare Award, for its natural approach to sustainable weight management without pharmaceutical interventions.
NY Wellness Solutions Inc., led by Dr. Howard Goodman, received recognition from Four Leaf Credit Union's Best of Long Island program and won the Long Island Choice Award for Best…
Luxury Apartments in Plano TX Offering Up to 8 Weeks Free Rent - Video Tours Now …
Luxury apartments in Plano TX are now offering up to 8 weeks free rent on select units. Local apartment locator Gerald Enriquez, founder of ApartmentsPlanoTX.com, makes the search easier with exclusive video tours on his YouTube channel. Renters can preview upscale communities from Legacy West to Downtown Plano and beyond, then complete a quick survey online to get matched with the best current deals.
Plano, TX - September 22, 2025 -…
CopperJoint's Odor-Resistant Copper Compression Socks for Women and Men Offer Al …
CopperJoint has launched a powerful update to its best-selling socks: men's and copper compression socks women trust for odor control, seamless comfort, and 15-20 mmHg graduated compression. From office meetings to 12-hour shifts, these socks provide sleek support without bulk. "This is next-level relief and recovery, packed into a sock that looks as sharp as it feels."
NASHVILLE, TN - September 22, 2025 - CopperJoint, a leader in copper-infused wellness wear,…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
